STUDY TITLE
A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.
STUDY DESIGN
Multicentre, open label, randomised phase 2 study
CORRELATIVE STUDIES
Samples of blood and bone marrow are collected for additional studies into natural killer cell response to therapy and biomarker analysis
TRIAL PRINCIPAL INVESTIGATOR
Associate Professor Peter Mollee
TIME FRAME
2017 – 2021
PARTICIPANTS
120 newly diagnosed multiple myeloma patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant
TOTAL ENROLLMENT
120
STATUS
Closed to recruitment
SITE LOCATIONS
-
Canberra Hospital, ACT
-
Blacktown Hospital, NSW
-
Westmead Hospital, NSW
-
ICON Cancer Care, QLD
-
Alfred Hospital, VIC
-
Barwon Health, VIC
-
Box Hill Hospital, VIC